Perjeta (pertuzumab)

PERJETA is a HER2/neu receptor antagonist indicated for:

  • Use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

  • Use in combination with trastuzumab and chemotherapy as:
    o Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.
    o Adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence

If a patient becomes pregnant while receiving PERJETA and Herceptin, or within 7 months following the last dose of PERJETA and Herceptin, please immediately report pregnancy to the local Roche Adverse Event Line at +92 301 8287010 or email at


Pharma Products
See all Pharma Products

This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.

please be aware that you are leaving this website.